Is fidaxomicin worth the cost? the verdict is still out!

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 604-605

  Hartzema, Abraham G ^a   Chen, Chao ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; GROUPS BY AGE; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; CLOSTRIDIUM INFECTIONS; ECONOMICS; FEMALE; ISOLATION AND PURIFICATION; MALE; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE;

EID: 84893226677     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit774     Document Type: Letter

References (10)

1. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57: 555-61.
2. United States Department of Health and Human Services. HCUP facts and figures: statistics on hospital-based care in the United States. Rockville, MD: Agency for Healthcare Research and Quality, 2009. Available at: http://www.hcup-us.ahrq.gov/reports/factsandfigures/2009/TOC-2009.jsp, Accessed 27 November 2013.
3. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
4. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-9.
5. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194-201.
6. Zar FA, Bakkangari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
7. Cepheid. Xpert C. difficile/Epi brochure. Sunnyvale, CA: Cepheid, Available at: http://www.cepheid.com/media/files/brochures/Xpert %20C.Diff%20Epi%20US%20Brochure%2003 30-02%20LOR.pdf. Accessed 27 November 2013.
8. Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005; 66:835-9.
9. Penson D, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing agonist in men with metastatic prostate cancer. J Urol 2005; 174:547-52.
10. Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ 1994; 3:157-68.